Skip to main
BNTX

BioNTech SE (BNTX) Stock Forecast & Price Target

BioNTech SE (BNTX) Analyst Ratings

Based on 13 analyst ratings
Buy
Strong Buy 54%
Buy 23%
Hold 23%
Sell 0%
Strong Sell 0%

Bulls say

BioNTech is a promising stock due to their growing oncology pipeline, including a successful cancer immunotherapy drug, Comirnaty. The company's collaborations with leaders like Pfizer and Merck, along with their potential for accelerated approval and a well-structured financial outlook, make it a positive investment choice. With their diversified approach to multiple diseases, BioNTech shows strong potential for long-term success.

Bears say

BioNTech is facing several risks, including negative data for its various pipeline drugs, slower market uptake, and failure to advance programs in a timely manner. Additionally, clinical and regulatory risks could delay revenue generation and impact the company's financial projections. The recent departure of BioNTech's co-founders to focus on a new mRNA biotech company also raises concerns about the company's commitment to its current oncology focus and partnership with Bristol-Myers Squibb. While the company has potential in its pipeline and partnerships, these risks lead to a negative outlook for BioNTech's stock.

BioNTech SE (BNTX) has been analyzed by 13 analysts, with a consensus rating of Buy. 54% of analysts recommend a Strong Buy, 23% recommend Buy, 23% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of BioNTech SE and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About BioNTech SE (BNTX) Forecast

Analysts have given BioNTech SE (BNTX) a Buy based on their latest research and market trends.

According to 13 analysts, BioNTech SE (BNTX) has a Buy consensus rating as of Aug 2, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $128, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $128, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

BioNTech SE (BNTX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.